Daily Bulletin


The Conversation

  • Written by Darren Saunders, Associate professor, UNSW
Many women with breast cancer may not need chemo, but beware misleading headlines

Findings from a major international clinical trial suggest a significant number of women with the most common form of early-stage breast cancer do not need chemotherapy after surgery.

The results of the so-called TAILORx trial were presented yesterday at the annual meeting of the American Society of Clinical Oncology and concurrently published in the New England Journal of Medicine.

Breast cancer types

The study looked at over 10,000 women with one specific type of breast cancer known as hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, lymph node–negative breast cancer.

Not all breast tumours behave the same way, with a number of different subtypes of breast cancer defined by genetic and protein markers. There are five to six main subtypes, depending on the classification system used. But with genome sequencing it’s becoming apparent each patient’s disease has subtle differences at the molecular level. These different subtypes are treated differently, and can have significantly different outcomes for patients.

Read more: What causes breast cancer in women? What we know, don't know and suspect

The subset of breast tumours that form the focus of this study are driven by hormones (oestrogen), do not respond to drugs such as trastuzumab (also known as Herceptin - an engineered antibody that targets HER2), and haven’t yet spread to the lymph nodes. They represent roughly half of the more than 17,000 new cases of breast cancer diagnosed in Australia every year.

Patients with these kind of tumours typically undergo surgery followed by treatment with drugs that target rapidly dividing cells (chemotherapy) and drugs that block the production or action of the hormone oestrogen (endocrine therapy, such as the drug Tamoxifen).

Results from this study suggest many women with this specific type of tumour do not receive any additional benefit from having chemotherapy in combination with endocrine therapy, compared to endocrine therapy alone. This has the potential to spare thousands of women from the awful side effects of chemotherapy, including nausea, hair loss, and heart and nerve damage.

This study used a genetic test (called “Oncotype DX”) to measure a panel of 21 genes that help predict risk of cancer recurrence. Importantly, chemotherapy still showed some benefit in women with higher Oncotype recurrence scores, and in some women under the age of 50.

Although mortality rates have decreased significantly over the last few decades, breast cancer is estimated to cause more than half a million deaths globally every year. Breast cancer remains the second most common cause of death from cancer among females in Australia.

Read more: My cancer is in remission – does this mean I'm cured?

Hope and hype

Cancer is complex and challenging to study, and news reporting on the disease easily lends itself to hype, contradiction and misinterpretation. Clearly communicating research findings are important for helping patients make informed decisions about treatment and modifying risk.

Poor reporting may have serious consequences for public and scientific communities alike. Some of the reports and headlines on this trial have been a little misleading, feeding on an understandable fear. They could potentially encourage patients to incorrectly avoid or stop treatment - with potentially tragic consequences.

False or unmet expectations can also seed disappointment and an eventual loss of trust in science. Another, more sinister, aspect to these headlines is the potential to fuel myths and conspiracy theories about the effectiveness of chemotherapy.

One of the most exciting aspects of this trial is the emergence of robust, large-scale data supporting the use of “precision medicine” - using genetic profiles to dictate treatment and predict outcomes in cancer. Trials like this are critical in balancing the significant hope and hype of precision medicine.

This study supports sparing thousands of women from the sometimes nasty side-effects of chemotherapy, but we must be crystal clear that it applies to a very specific (and significant) subset of women. Patients should not make any changes to their treatment based off this study, and should always consult their doctors.

And while celebrating this genuine advance, we should remember just how far we have to go in finding effective therapies for metastatic breast cancer, and other breast cancer subtypes for which treatment options are still limited.

Read more: How likely is my breast cancer to recur and spread?

Authors: Darren Saunders, Associate professor, UNSW

Read more http://theconversation.com/many-women-with-breast-cancer-may-not-need-chemo-but-beware-misleading-headlines-97686

Writers Wanted

As Trump exits the White House, he leaves Trumpism behind in Australia

arrow_forward

Biden’s Senate majority doesn't just super-charge US climate action, it blazes a trail for Australia

arrow_forward

Disaster season is here — do you have a Resilience Action Plan? Here's how the small town of Tarnagulla built theirs

arrow_forward

The Conversation
INTERWEBS DIGITAL AGENCY

Politics

Prime Minister's Remarks to Joint Party Room

PRIME MINISTER: Well, it is great to be back in the party room, the joint party room. It’s great to have everybody back here. It’s great to officially welcome Garth who joins us. Welcome, Garth...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Ben Fordham, 2GB

BEN FORDHAM: Scott Morrison, good morning to you.    PRIME MINISTER: Good morning, Ben. How are you?    FORDHAM: Good. How many days have you got to go?   PRIME MINISTER: I've got another we...

Scott Morrison - avatar Scott Morrison

Prime Minister Interview with Kieran Gilbert, Sky News

KIERAN GILBERT: Kieran Gilbert here with you and the Prime Minister joins me. Prime Minister, thanks so much for your time.  PRIME MINISTER: G'day Kieran.  GILBERT: An assumption a vaccine is ...

Daily Bulletin - avatar Daily Bulletin

Business News

7 foolproof tips for bidding successfully at a property auction

Auctions can be beneficial for prospective buyers, as they are transparent and fair. If you reach the limit you are willing to pay, you can simply walk away. Another benefit of an auction is tha...

Dominique Grubisa - avatar Dominique Grubisa

Getting Ready to Code? These Popular and Easy Programming Languages Can Get You Started

According to HOLP (History Encyclopedia of Programing Languages), there are more than 8,000 programming languages, some dating as far back as the 18th century. Although there might be as many pr...

News Co - avatar News Co

Avoid These Mistakes When Changing up Your Executive Career

Switching up industries is a valid move at any stage in your career, even if you’re an executive. Doing so at this stage can be a lot more intimidating, however, and it can be quite difficult know...

News Co - avatar News Co



News Co Media Group

Content & Technology Connecting Global Audiences

More Information - Less Opinion